Aligos Therapeutics to Present at the H.C. Wainwright Liver Disease Conference

Rhea-AI Summary

Aligos Therapeutics (Nasdaq: ALGS) will present at the H.C. Wainwright Liver Disease Conference on October 21–22, 2025. Members of management will deliver a company presentation covering recent clinical and corporate developments.

Investors can watch a live webcast via the Presentation & Events section on Aligos’ investor website at www.aligos.com. A replay will be available for at least 30 days after the presentation.

SOUTH SAN FRANCISCO, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will present at the H.C. Wainwright Liver Disease Conference being held October 21 - 22, 2025.

A webcast of the presentation will be accessible by visiting the Presentation & Events section on the “Investors” page of Aligos’ website at www.aligos.com. A replay of the webcast will be available following the presentation for at least 30 days.

About Aligos

Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for high unmet medical needs such as chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses.

For more information, please visit www.aligos.com or follow us on LinkedIn or X.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding Aligos’ financial results and performance as well as research and development activities, including regulatory status and the timing of announcements and updates relating to our regulatory filings and clinical trials. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, and other matters that could affect the sufficiency of Aligos’ capital resources to fund operations. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2025 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.  

Aligos Therapeutics

Contact
Jordyn Tarazi
Vice President, Investor Relations & Corporate Communications
+1 (650) 910-0427
jtarazi@aligos.com

Media Contact
Inizio Evoke
Jake Robison
Vice President
Jake.Robison@inzioevoke.com

FAQ

When will Aligos Therapeutics (ALGS) present at the H.C. Wainwright Liver Disease Conference in 2025?

Aligos will present on October 21–22, 2025 during the conference dates.

How can investors watch the Aligos (ALGS) presentation at the October 2025 conference?

Investors can watch a live webcast on the Presentation & Events section of Aligos’ investor website at www.aligos.com.

Will there be a replay of the Aligos (ALGS) webcast after the H.C. Wainwright Liver Disease Conference?

Yes. A replay of the webcast will be available on Aligos’ investor site for at least 30 days following the presentation.

What topics will Aligos (ALGS) management likely cover at the October 2025 Liver Disease Conference?

Management will discuss recent clinical and corporate developments related to Aligos’ liver and viral disease programs.

Where on Aligos’ website is the October 2025 conference webcast posted?

The webcast is posted in the Presentation & Events section of the company’s Investors page at www.aligos.com.

How long will the Aligos (ALGS) presentation replay remain available after October 2025?

The replay will remain available for at least 30 days after the live presentation.